Yissum’s CEO to leave
Ms Sofer was appointed in December 2005 to lead Yissum. She joined Yissum from the venture capital industry where she held a series of senior roles in Israel
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.